• About us
• Contact

Advertisement

Organisation › Details

Abingworth Management Ltd.

Abingworth is a leading transatlantic life sciences investment firm with over $2 billion under management. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 179 life science companies, leading to 46 M&As and 73 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. *

 

	Start	2000-03-01 existent
	Industry	venture capital
	Person	Haines, Timothy (Tim) (Abingworth 201507– Managing Partner joined 2005 before Astex CEO)
	Person 2	von Emster, Kurt (Abingworth 201507– Managing Partner joined 201501 before venBio + MPM Capital + Franklin Templeton)
	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	38 Jermyn Street
	City	SW1Y 6DN London
	Tel	+44-20-7534-1500
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	2,000,000,000 (capital under management (2022) 2022-04-11)
		* Document for »About Section«: Carlyle Group, The. (4/11/22). "Press Release: Carlyle Expands Leading Healthcare Franchise with Agreement to Acquire Life Sciences Investment Firm Abingworth". New York, NY.
		Record changed: 2023-10-31

Advertisement

More documents for Carlyle (Group)

• [1] Carlyle Group, The. (4/11/22). "Press Release: Carlyle Expands Leading Healthcare Franchise with Agreement to Acquire Life Sciences Investment Firm Abingworth". New York, NY....
• [2] Glycomine, Inc.. (12/17/21). "Press Release: Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease". San Carlos, CA....
• [3] Anjarium Biosciences AG. (9/16/21). "Press Release: Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies". Schlieren....
• [4] Abingworth LLP. (9/15/21). "Press Release: Abingworth Strengthens Investment Team with New Appointments in the US and UK". London....
• [5] Abingworth LLP. (5/10/21). "Press Release: Abingworth Raises $582 Million for New Clinical Co-Development Fund – ACCD 2". London....
• [6] Abingworth LLP. (2/3/21). "Press Release: Abingworth Raises $465m for New Life Sciences Fund Abingworth Bioventures 8". London....
• [7] GHO Capital Partners LLP. (6/3/20). "Press Release: GHO Capital Acquires X-Chem, a Leading Drug Discovery Service Provider". London....
• [8] Jasper Therapeutics, Inc.. (12/6/19). "Press Release: Jasper Therapeutics Launches with $35 Million Series A Financing to Develop and Commercialize Innovative Conditioning Agents and Therapies to Transform Curative Hematopoietic Cell Transplants". Palo A...
• [9] Abingworth LLP. (7/9/18). "Press Release: Abingworth Raises $315m for ABV VII 12th Life Sciences Fund". London....
• [10] Nouscom AG. (11/6/17). "Press Release: NousCom Raises €42 Million Series B Financing". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.